The scientist’s investigation covers issues in Immunology, Immunotherapy, Epitope, Antigen and Human leukocyte antigen. Yasuharu Nishimura combines subjects such as Cancer cell, Cancer, Cancer research and Cytotoxic T cell with his study of Immunology. His biological study deals with issues like CTL*, which deal with fields such as Antibody, Virology and Immunosurveillance.
His Epitope research integrates issues from T cell, Dendritic cell and Immune system. His Antigen study integrates concerns from other disciplines, such as Cell and Vaccination. His biological study spans a wide range of topics, including Allele and Immunopathology.
His scientific interests lie mostly in Immunology, Antigen, Immunotherapy, Molecular biology and Human leukocyte antigen. His Immunology research incorporates themes from Cytotoxic T cell and Cancer research. His research investigates the connection between Antigen and topics such as Antibody that intersect with problems in Pathology.
His work carried out in the field of Immunotherapy brings together such families of science as Adoptive cell transfer and CTL*. His research investigates the link between Human leukocyte antigen and topics such as Allele that cross with problems in Multiple sclerosis. Within one scientific family, Yasuharu Nishimura focuses on topics pertaining to T cell under Epitope, and may sometimes address concerns connected to Signal transduction.
Yasuharu Nishimura mainly investigates Immunology, Cancer research, Antigen, Immunotherapy and Cancer immunotherapy. His Immunology study combines topics from a wide range of disciplines, such as Cytotoxic T cell, Cancer and Cellular differentiation. Yasuharu Nishimura has included themes like Tumor microenvironment, CD8, Induced pluripotent stem cell and Immune checkpoint in his Cancer research study.
Epitope and Major histocompatibility complex are among the areas of Antigen where he concentrates his study. His Epitope research is multidisciplinary, incorporating perspectives in Cell, Immunogenicity, Peptide sequence, Human leukocyte antigen and Peptide. His study explores the link between Immunotherapy and topics such as ELISPOT that cross with problems in Peptide vaccine and Colorectal cancer.
His primary scientific interests are in Immunology, Cancer immunotherapy, Antigen, Epitope and Immune system. Yasuharu Nishimura interconnects In vitro and Cellular differentiation in the investigation of issues within Immunology. His research in Antigen intersects with topics in Cytotoxic T cell, Molecular biology and Vaccination.
His work deals with themes such as Peripheral blood mononuclear cell, Immunogenicity and Antigen-presenting cell, which intersect with Molecular biology. His Epitope research focuses on Cell and how it connects with Cancer cell. His Immune system study deals with Interleukin intersecting with Cell therapy, Interleukin 6, T cell, Acquired immune system and Inflammation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.
Tetsuya Nakatsura;Yoshihiro Yoshitake;Satoru Senju;Mikio Monji.
Biochemical and Biophysical Research Communications (2003)
Western versus asian types of multiple sclerosis: Immunogenetically and clinically distinct disorders
Jun Ichi Kira;Takayuki Kanai;Yasuharu Nishimura;Kenji Yamasaki.
Annals of Neurology (1996)
Ribosome stalling induced by mutation of a CNS-specific tRNA causes neurodegeneration
Ryuta Ishimura;Gabor Nagy;Ivan Dotu;Huihao Zhou.
Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Hiroyuki Komori;Tetsuya Nakatsura;Satoru Senju;Yoshihiro Yoshitake.
Clinical Cancer Research (2006)
Identification of glypican-3 as a novel tumor marker for melanoma.
Tetsuya Nakatsura;Toshiro Kageshita;Shosuke Ito;Kazumasa Wakamatsu.
Clinical Cancer Research (2004)
HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies.
Kenji Yamasaki;Izumi Horiuchi;Motozumi Minohara;Yuji Kawano.
Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Hirotake Tsukamoto;Koji Fujieda;Azusa Miyashita;Satoshi Fukushima.
Cancer Research (2018)
Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy
S Senju;M Haruta;K Matsumura;Y Matsunaga.
Gene Therapy (2011)
Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand.
Shinya Hirata;Satoru Senju;Hidetake Matsuyoshi;Daiki Fukuma.
Journal of Immunology (2005)
Peptides and drugs containing the same
Yasuharu Nishimura;Tetsuya Nakatsura;Yusuke Nakamura.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: